For more than a decade, computational scientist Juan R. Perilla of the University of Delaware has been working to digitally reconstruct a very particular structure of the human immunodeficiency virus (HIV). Perilla and his colleagues set out to create an active three-dimensional digital model of the virus shell, or capsid, that researchers could study and probe as if they were working with an actual particle. The processing power required to build the simulation was significant, according to Perilla, because the model needed to track how a change in one area would impact the interactions of all two million atoms in the particle. Perilla and his group succeeded in constructing the model and demonstrating various means of testing the simulation to ensure it behaves as it would in the real world. "You can actually interrogate the simulated particle, pushing and pulling on the capsid as if you were testing the actual physical system," Perilla says.

Google's Chromebook has become ubiquitous in classrooms across the United States, often considered the go-to option for digital learning given its relative affordability and web-based programs -- a combination that proved even more valuable for distance learning during the height of the COVID-19 pandemic. Since Chromebooks' launch more than a decade ago as a cheaper alternative to tablets, their use has expanded exponentially in schools nationwide, providing more students a personal computer device -- including in many low-income districts. And although issues of internet connection and at-home access to devices persist, new improvements to the Chromebook could help stretch its lifetime and scope. Google recently announced plans to expand Chromebooks' automatic updates up to 10 years, maximizing the potential lifespan of the devices that have become key for both in-school lessons and after-school studies. Beginning next year, the change will automatically apply to all Chromebooks launched in 2021 or later, and for devices released before 2021 there will be an option to extend the updates to 10 years from the platform's original release, Google officials said.

Fox News Flash top headlines are here. Check out what's clicking on Foxnews.com. The life sciences industry is right to be optimistic about the potential of generative AI. Biotech startups are already testing AI-generated drugs in clinical trials with human patients. Researchers have estimated that AI-powered drug discovery could drive as much as $50 billion in economic value over the next decade.

Fox News Flash top headlines are here. Check out what's clicking on Foxnews.com. Northeastern University in Boston will be given $17.5 million by the Centers for Disease Control and Prevention (CDC) to lead an innovation center focused on infectious disease detection and preparation, the university announced. The Center for Advanced Epidemic Analytics and Predictive Modeling Technology, or EPISTORM, will "help detect and prepare the United States for the next outbreak of infectious disease, especially in rural areas," according to the university's Northeastern Global News (NGN). The funds will be used to coordinate the work of various consortium members across the U.S. to prepare local communities for outbreaks, including RSV and the seasonal flu.

The news: Self-driving car startup Wayve can now interrogate its vehicles, asking them questions about their driving decisions--and getting answers back thanks to a chatbot. How it works: The idea is to use the same tech behind ChatGPT to help train driverless cars. The company combined its existing self-driving software with a large language model, creating a hybrid model that syncs up video data and driving data with natural-language descriptions that capture what the car sees and what it does. Why it matters: Wayve is treating the news as a breakthrough in AI safety. By quizzing its self-driving software every step of the way, Wayve hopes to understand exactly why and how its cars make certain decisions--and to uncover mistakes more quickly.

Malaria is an infectious disease claiming more than half a million lives each year. Because traditional diagnosis takes expertise and the workload is high, an international team of researchers investigated if diagnosis using a new system combining an automatic scanning microscope and AI is feasible in clinical settings. They found that the system identified malaria parasites almost as accurately as experts staffing microscopes used in standard diagnostic procedures. This may help reduce the burden on microscopists and increase the feasible patient load. Each year, more than 200 million people fall sick with malaria and more than half a million of these infections lead to death. The World Health Organization recommends parasite-based diagnosis before starting treatment for the disease caused by Plasmodium parasites.

Deciding how to regulate AI is one of the biggest challenges facing politicians and experts alike. Melissa Heikkilä, our senior reporter for AI, will be chatting with news editor Charlotte Jee about what should be done to keep AI companies in line. Roundtables are free for MIT Technology Review subscribers, so if you're not already, you can become one today from just $80 a year.

PsychoGenics CEO Emer Leahy of Paramus, New Jersey, explains how the first potential AI-discovered treatment for schizophrenia was developed through machine learning. Fox News Digital spoke with her. COVID: Artificial intelligence-generated COVID drug enters clinical trials. WORK TOGETHER: Embracing AI means we must mitigate risk to firms, industries, consumers and society. TERRIFYING TECH: Criminal enterprise flaunts AI in creepy commercial meant for dark web.

PsychoGenics CEO Emer Leahy of Paramus, New Jersey, explains how the first potential AI-discovered treatment for schizophrenia was developed through machine learning. Fox News Digital spoke with her. Artificial intelligence is increasingly moving into the health care arena and helping to streamline medical processes -- including the creation of new drugs. Insilico Medicine, an AI-driven biotech company based in Hong Kong and in New York City, recently announced that its new AI-designed drug for COVID-19 has entered Phase I clinical trials. This oral drug is a treatment, not a vaccine.

AFTER dodging covid-19 for several years, I finally tested positive for one of the leading causes of death where I live in the US. I'm vaccinated, but also in a statistically vulnerable group: I'm over 50, and I used to smoke. For people like me, the US Centers for Disease Control and Prevention recommends treatments including the new drug Paxlovid.